Andrew Fein (H.C. Wainwright) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Andrew Fein's stock ratings?

About 48% of Andrew's ratings were profitable over a one-year hold, with an average return of +10.4% per rating, measured by 13Foresight from historical prices.

Q: How is Andrew ranked?

Andrew Fein is ranked #2400 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Andrew Fein

Andrew Fein

H.C. Wainwright

Wall Street Analyst

★☆☆☆☆

#2400

on 13Foresight · ranked by our own returns

48%

Success Rate

+10.5%

Average Return

29 of 61 calls profitable · -218.9% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 48% of Andrew Fein's ratings turned a profit when each position was held for 1 year — averaging +10.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

218 Buy 12 Hold 0 Sell

Andrew's Stock Coverage 65 ratings · 2026-06-21

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
AMLX Amylyx Pharmaceuticals Inc	Jun 16, 2026	BUY	Strong Buy +46.8% avg upside 13 analysts	$34.00 117.01% Upside	+1.3%
SVRA Savara	Jun 15, 2026	BUY	Strong Buy +57.8% avg upside 17 analysts	$10.00 81.76% Upside	·
WVE Wave Life Sciences	Jun 11, 2026	BUY	Strong Buy +260.5% avg upside 28 analysts	$13.00 111.07% Upside	+6.0%
PVLA Palvella Therapeutics	Jun 11, 2026	BUY	Strong Buy +45.3% avg upside 27 analysts	$270.00 138.72% Upside	+6.3%
MTVA MetaVia	Jun 09, 2026	BUY	Strong Buy +1769.3% avg upside 13 analysts	$20.00 1150.00% Upside	·
LQDA Liquidia Technologies	Jun 05, 2026	BUY	Strong Buy -28.5% avg upside 15 analysts	$75.00 5.54% Upside	+11.0%
FULC Fulcrum Therapeutics	Jun 02, 2026	HOLD	Hold +138.4% avg upside 13 analysts	$3.00 18.89% Downside	·
CPRX Catalyst Pharma	May 29, 2026	HOLD	Strong Buy -17.0% avg upside 15 analysts	$31.50 0.37% Upside	+0.5%
UTHR United Therapeutics	May 29, 2026	BUY	Strong Buy -18.7% avg upside 26 analysts	$660.00 22.95% Upside	-3.6%
MDGL Madrigal Pharmaceuticals	May 28, 2026	BUY	Strong Buy -5.8% avg upside 31 analysts	$620.00 22.55% Upside	-2.0%
ARVN Arvinas Holding Company	May 22, 2026	BUY	Strong Buy +264.5% avg upside 27 analysts	$18.00 134.61% Upside	-16.6%
DNLI Denali Therapeutics	May 22, 2026	BUY	Strong Buy +60.2% avg upside 24 analysts	$42.00 80.18% Upside	+17.6%
BIIB Biogen	May 14, 2026	BUY	Strong Buy +25.1% avg upside 51 analysts	$237.00 20.53% Upside	+3.8%
IL:KMDA Kamada	May 14, 2026	BUY	Strong Buy +78.0% avg upside 7 analysts	$3847.69 81.64% Upside	·
ARCT Arcturus Therapeutics	May 13, 2026	HOLD	Buy +290.9% avg upside 35 analysts	$9.00 19.53% Upside	·
INSM Insmed	May 08, 2026	BUY	Strong Buy +82.2% avg upside 36 analysts	$220.00 129.60% Upside	-2.9%
ALEC Alector	May 08, 2026	BUY	Hold +532.1% avg upside 14 analysts	$5.00 185.76% Upside	+2.9%
PRTA Prothena	May 08, 2026	BUY	Buy +160.9% avg upside 14 analysts	$30.00 235.93% Upside	-20.9%
BCRX BioCryst	May 07, 2026	BUY	Strong Buy +103.3% avg upside 24 analysts	$32.00 255.96% Upside	-5.3%
VRTX Vertex Pharmaceuticals	May 04, 2026	BUY	Strong Buy -2.6% avg upside 61 analysts	$641.00 41.94% Upside	+6.8%
KYMR Kymera Therapeutics	May 04, 2026	BUY	Strong Buy +8.9% avg upside 36 analysts	$134.00 48.26% Upside	+7.5%
NBIX Neurocrine	May 04, 2026	BUY	Strong Buy +7.8% avg upside 37 analysts	$215.00 35.75% Upside	+19.2%
ACIU AC Immune SA	May 01, 2026	BUY	Strong Buy +233.3% avg upside 5 analysts	$12.00 399.94% Upside	-6.4%
DBVT DBV Technologies SA - American	May 01, 2026	BUY	Strong Buy +55.4% avg upside 15 analysts	$40.00 157.59% Upside	-18.1%
ACAD ACADIA Pharmaceuticals	May 19, 2025	BUY	Strong Buy +65.9% avg upside 42 analysts	$32.00 48.06% Upside	-6.9%
STOK Stoke Therapeutics	May 15, 2025	BUY	Strong Buy +25.1% avg upside 18 analysts	$35.00 12.91% Upside	+212.4%
ABOS Acumen Pharmaceuticals	May 14, 2025	HOLD	Strong Buy +258.9% avg upside 10 analysts	—	+143.9%
ANNX Annexon Biosciences	May 12, 2025	BUY	Strong Buy +181.2% avg upside 13 analysts	$14.00 185.63% Upside	+207.3%
PRQR ProQR	May 09, 2025	BUY	Strong Buy +516.3% avg upside 18 analysts	$12.00 535.01% Upside	-1.9%
PEPG PepGen Inc.	May 09, 2025	BUY	Strong Buy +493.6% avg upside 8 analysts	$14.00 682.11% Upside	+17.3%
DYN Dyne Therapeutics	May 09, 2025	BUY	Strong Buy +92.7% avg upside 29 analysts	$38.00 91.83% Upside	+54.3%
NBP NovaBridge Biosciences	Apr 04, 2025	BUY	Strong Buy +1309.7% avg upside 14 analysts	$7.00 366.69% Upside	·
KROS Keros Therapeutics	Apr 01, 2025	BUY	Strong Buy +139.0% avg upside 21 analysts	$40.00 275.60% Upside	+22.4%
ZNTL Zentalis Pharmaceuticals	Mar 27, 2025	BUY	Buy +292.3% avg upside 16 analysts	$10.00 170.28% Upside	+17.3%
STRO Sutro Biopharma	Mar 17, 2025	HOLD	Strong Buy +31.6% avg upside 20 analysts	$20.00 32.41% Downside	+146.7%
FHTX Foghorn Therapeutics	Mar 07, 2025	BUY	Strong Buy +187.5% avg upside 17 analysts	$13.00 213.21% Upside	+27.9%
TCRX TScan Therapeutics	Mar 06, 2025	BUY	Strong Buy +823.9% avg upside 12 analysts	$15.00 1530.38% Upside	-46.2%
TARA Protara Therapeutics	Mar 05, 2025	BUY	Strong Buy +1154.4% avg upside 21 analysts	$23.00 477.83% Upside	+60.3%
SYRS Syros Pharmaceuticals	Feb 28, 2025	HOLD	Buy +11749900.0% avg upside 9 analysts	—	-99.9%
CRBP Corbus Pharmaceuticals	Feb 18, 2025	BUY	Strong Buy +337.2% avg upside 20 analysts	$75.00 808.04% Upside	-9.7%
CCCC C4 Therapeutics	Feb 26, 2024	HOLD	Strong Buy +330.3% avg upside 19 analysts	—	-72.1%
PULM Pulmatrix	Nov 13, 2023	BUY	Strong Buy +585.0% avg upside 1 analyst	$10.00 585.00% Upside	+98.9%
LITS Lite Strategy	Feb 13, 2023	BUY	Strong Buy +1215.4% avg upside 13 analysts	$40.00 4732.11% Upside	·
MTNB Matinas BioPharma	Jan 31, 2023	BUY	Buy +2193.0% avg upside 7 analysts	$3.00 396.77% Upside	-65.3%
AMRN Amarin	Oct 28, 2022	HOLD	Buy -47.3% avg upside 18 analysts	$3.00 81.23% Downside	-43.9%
ELOX Eloxx Pharmaceuticals	May 09, 2022	HOLD	Strong Buy +153.9% avg upside 8 analysts	$20.00 43.06% Upside	-64.5%
QNCX Quince Therapeutics	Mar 22, 2022	BUY	Hold +2750.2% avg upside 13 analysts	$15.00 1487.07% Upside	-76.4%
APRE Aprea Therapeutics	Mar 16, 2022	HOLD	Buy +3098.2% avg upside 7 analysts	$40.00 5494.44% Upside	-87.1%
GRCE Grace Therapeutics	Aug 14, 2020	BUY	Strong Buy +153.0% avg upside 9 analysts	$3.00 26.00% Upside	-36.6%
COGT Cogent Biosciences	Mar 27, 2020	BUY	Strong Buy +7.1% avg upside 26 analysts	$16.00 53.69% Downside	+368.9%
BGMS Bio Green Med Solution	Feb 27, 2020	BUY	Strong Buy +1647.8% avg upside 7 analysts	$7.00 823.45% Upside	-36.1%
ANAB AnaptysBio	Aug 12, 2019	BUY	Strong Buy +26.1% avg upside 26 analysts	$126.00 119.03% Upside	-62.2%
DCOY Decoy Therapeutics	May 03, 2018	BUY	Strong Buy +338.9% avg upside 7 analysts	$40.00 559.01% Upside	·
TPST Tempest Therapeutics	Mar 16, 2018	BUY	Buy +1669.9% avg upside 18 analysts	$15.00 1119.45% Upside	-4.6%
ANTH Anthera Pharmaceuticals	Mar 06, 2018	BUY	Buy +472857042.9% avg upside 9 analysts	$3.00 299999899.95% Upside	·
ATNM Actinium Pharmaceuticals	May 08, 2017	BUY	Strong Buy +633.5% avg upside 11 analysts	$8.00 676.60% Upside	-74.4%
LADX LadRx	Apr 20, 2017	BUY	Strong Buy +6535.5% avg upside 5 analysts	$4.00 3638.31% Upside	·
TGTX TG Therapeutics	Mar 07, 2017	BUY	Strong Buy -34.4% avg upside 19 analysts	$18.00 66.25% Downside	·
ESI Element Solutions	Jan 20, 2017	BUY	Strong Buy -33.9% avg upside 17 analysts	$5.00 89.10% Downside	+1.6%
WINT Windtree Therapeutics	Oct 28, 2016	BUY	Strong Buy +40610.2% avg upside 6 analysts	$8.00 46986.53% Upside	·
TOVX Theriva Biologics	Jun 04, 2015	BUY	Strong Buy +3100.9% avg upside 8 analysts	$4.00 1492.89% Upside	-16.7%
ABEO Abeona Therapeutics	May 18, 2015	BUY	Strong Buy +195.8% avg upside 17 analysts	$15.00 160.04% Upside	-72.9%
LSTA Lisata Therapeutics	Nov 19, 2014	BUY	Buy +267.9% avg upside 11 analysts	$20.00 468.11% Upside	-73.7%
NEPTF Neptune Wellness Solutions	Oct 03, 2014	BUY	Strong Buy +401611971.0% avg upside 7 analysts	$9.00 899999899.91% Upside	·
ALT Altimmune	Aug 11, 2014	BUY	Strong Buy +935.8% avg upside 19 analysts	$4.00 48.12% Upside	·

🔒 60 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Andrew Fein — Frequently Asked Questions

How accurate are Andrew Fein's stock ratings?

Based on the calls 13Foresight could measure, about 48% of Andrew's ratings were profitable over a one-year hold, with an average return of +10.4% per rating, or -2126.5% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Andrew ranked on 13Foresight?

Andrew Fein is currently ranked #2400 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Andrew cover?

Andrew most recently has ratings on AMLX, SVRA, WVE, PVLA, MTVA, LQDA, FULC, CPRX, UTHR, MDGL, ARVN, DNLI and 53 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!